Phase II Trial of Reduced Intensity Conditioning (RIC) and Allogeneic Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Event Free Survival
Number of subjects surviving with no events at 180 days post transplantation (Day 0).
Mary J. Laughlin, MD
University of Virginia
United States: Food and Drug Administration
|University of Virginia||Charlottesville, Virginia 22908|